Phase II trial of prednimustine in glioblastoma multiforme.
Twenty-one consecutive patients with histologically confirmed glioblastoma multiforme were treated with prednimustine (130 mg/m2 for 5 days every 3 weeks) adjuvant to surgery and radiation therapy. A median survival of 8.7 months was obtained, and prednimustine seems to be of limited effectiveness. Toxicity was acceptable and primarily hematologic.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy*; D002699:Chlorambucil / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011238:Prednimustine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D002699:Chlorambucil; D011238:Prednimustine